Copaxone pushes Teva profits past $1b. mark in 2005

Net sales for Q4 of 2005 increased 6% over the comparable quarter last year to $1.4b., which was slightly below the consensus analysts' estimate of $1.42b.

By SHARON WROBEL
March 1, 2006 08:10
2 minute read.
teva logo 88

teva logo 88. (photo credit: )

 
X

Dear Reader,
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being forced to look for new ways to keep going. Unlike many other news organizations, we have not put up a paywall. We want to keep our journalism open and accessible and be able to keep providing you with news and analyses from the frontlines of Israel, the Middle East and the Jewish World.

As one of our loyal readers, we ask you to be our partner.

For $5 a month you will receive access to the following:

  • A user experience almost completely free of ads
  • Access to our Premium Section
  • Content from the award-winning Jerusalem Report and our monthly magazine to learn Hebrew - Ivrit
  • A brand new ePaper featuring the daily newspaper as it appears in print in Israel

Help us grow and continue telling Israel’s story to the world.

Thank you,

Ronit Hasin-Hochman, CEO, Jerusalem Post Group
Yaakov Katz, Editor-in-Chief

UPGRADE YOUR JPOST EXPERIENCE FOR 5$ PER MONTH Show me later Don't show it again

Teva Pharmaceutical Industries, the world's largest manufacturer of generic drugs on Tuesday reported a 9 percent increase in fourth quarter profits helped by strong sales of its multiple sclerosis drug Copaxone and the launch of other new generics. "It was a record-breaking year for us. Copaxone was our first blockbuster and it will not be the last," said Teva's chief executive officer Israel Makov. The Jerusalem-based company, which published its last financial report before its $7.6 billion merger with Ivax last month, reported that net profit for the fourth quarter of 2005 climbed to $305 million, or 45 cents per share, representing increases of 9% and 10%, respectively, over the same period in 2004. "On earnings per share Teva beat the consensus estimate, which was between 43 cents and our 44 cents forecast," said Yisca Erez, analyst at Clal Finance Batucha. "The higher EPS was supported by strong sales from Copaxone, the Allegra generic version launched in the third quarter, and the generic versions of Zithromax and Oxycontin launched in the fourth quarter." Net sales for the fourth quarter of 2005 increased 6% over the comparable quarter last year to $1.4 billion, which was slightly below the consensus analysts' estimate of $1.42b. For the full year, Teva recorded a net profit of $1.07b. or $1.59 per share, on net sales of NIS 5.3b. Global in-market sales of Teva's multiple sclerosis drug Copaxone reached a high of $323m. in the fourth quarter, representing an increase of 24% over the comparable quarter of 2004. For the full year of 2005, global in-market sales of Copaxone reached $1.176m representing an increase of 26% over 2004. Another contributor to Teva's strong results was a lower tax rate of 18% for 2005 compared with an annual estimated tax rate of 19.6% provided three months ago. The tax rate in the fourth quarter was 13.7%. Teva's US generic pipeline, including products acquired through the Ivax acquisition, currently comprises 160 product applications, including 38 tentative approvals relating to products with total branded sales of $94b. Of these product applications, 88 have been submitted to the U.S. Food & Drug Administration. Of those 88, 49, with total branded sales of $37b., are expected to be designated "first to file," which would provide Teva with periods of 180 days of marketing exclusivity. "There is a significant par between Teva's potential exclusivity pipeline presented today and the one Teva presented last quarter," said analysts at IBI. "In the last quarter, on the verge of the closure of the IVAX merger, Teva's pipeline comprised 145 product applications with total branded sales of $97b., of which 39 with total branded sales of $25b. were classified as potential 'first-file' product applications."

Related Content

The Teva Pharmaceutical Industries
April 30, 2015
Teva doubles down on Mylan, despite rejection

By GLOBES, NIV ELIS